PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
December 9, 2025New England Journal of Medicine78 citations

Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma

View Full Paper
LCLuciano J. CostaNBNizar J. BahlisAPAurore Perrot

Key Points

  • The goal was to compare the efficacy of teclistamab plus daratumumab in multiple myeloma patients.
  • Patients received teclistamab plus daratumumab regimen compared to DPd or DVd groups.
  • Participants had one to three previous lines of therapy.
  • The teclistamab-daratumumab group had significantly longer progression-free survival than those in DPd or DVd group.

Abstract

In patients with multiple myeloma who had received one to three previous lines of therapy, those in the teclistamab-daratumumab group had significantly longer progression-free survival than those in the DPd or DVd group. (Funded by Johnson ClinicalTrials.gov number, NCT05083169.).

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Costa et al. (2025) studied this question.

synapsesocial.com/papers/69401d682d562116f28f900chttps://doi.org/10.1056/nejmoa2514663
Ask AI
Helpful
Bookmark
Share
View Full Paper